23andMe is laying off 40 percent of its employees, or over 200 workers, as the company attempts to recover from last year’s massive data breach and reverse its plummeting stock price. The genetic testing company also announced that it will shut down its therapeutics business.

RELATED: Southwest Airlines to offer buyouts at 18 airports, headquarters The restructuring arrives during a period of turmoil at South San Francisco-based 23andMe, which has recently included a high-profile data breach, several rounds of previous layoffs ...

The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile data breach, several rounds of previous layoffs and piling losses that plunged the company's stock over recent years. Back in ...

The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies in development.

Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.

DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.

The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire workforce, according to a press release Monday. The move is part of a restructuring that will see the company also halt the development of its therapeutics division which had been working on various potential medical treatments.

Me is laying off 40% of its workforce right before the holiday season - The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile data breach,